JPMorgan analyst Anupam Rama upgraded Mirati Therapeutics (NASDAQ: MRTX) from Neutral to Overweight with a price target of $116.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE